ArticleScientific reports2021
Clostridium butyricum enhances colonization resistance against Clostridioides difficile by metabolic and immune modulation.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 59 citations in OpenAlex.
- Bifidobacterium breve PRL2020 mitigates antibiotic-induced gut symptoms and dysbiosis in children treated with amoxicillin or amoxicillin-clavulanate.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Trial
- Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.Nature medicine · 2024Trial
- Microbiome-based therapeutics forGut microbes · 2026Review
- Clinical analysis of 16 patients withNew microbes and new infections · 2026Article
- Article
- Amino acid metabolism by pig intestinal bacteria and consequences for intestinal health and environment: current knowledge and future directions.Journal of animal science and biotechnology · 2026Review
- The Nexus of Gut Microbiome, Microbial Metabolites, and Colonization Resistance Against Enteric Pathogens.Biomolecules · 2026Review
- A mixed prebiotic/probiotic intervention (MBR-01) for the management of diarrhea during abemaciclib treatment of early breast cancer in postmenopausal patients: A single-center prospective case-control pilot study.Breast (Edinburgh, Scotland) · 2026Article
- Clinical Outcomes of Metronidazole Monotherapy Versus Metronidazole PlusBiotech (Basel (Switzerland)) · 2026Article
- Immunotherapy with guts: a review of microbial therapeutic adjuncts for immunotherapy in solid tumors.The oncologist · 2026Review
- Attenuation ofJournal of microbiology and biotechnology · 2026Article
- Butyrate-Mediated Upregulation of Insulin Pathway Gene Expression Suggests Potential Antidiabetic Effects.Drug development research · 2025Article
- Recycling of Undigested Proteins Provided by the Host to the Large Intestine Microbiota: Implication for Intestinal Bacterial Anabolism, Growth, and Physiology.Microorganisms · 2025Review
- Liujunzi Decoction Regulated Intestinal Flora Homeostasis to Relieve Lung-Gut Axis Inflammation in Asthma Flora Disorder Mice: Possibly Related to GATA3/ILC2.Chinese journal of integrative medicine · 2025Article
- Article
- Analysis of single-cell RNA sequencing data to examine the gastric inflammation-to-cancer transition and evaluation of the effect of probiotic on precancerous lesions.Engineering microbiology · 2025Article
- The interplay between host immunity andmBio · 2025Review
- Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study.Cancer reports (Hoboken, N.J.) · 2025Article
- Comparative genomics ofMicrobial genomics · 2025Article
- Recent advances in therapeutic probiotics: insights from human trials.Clinical microbiology reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridioides difficile infection (CDI) represents the leading cause of nosocomial diarrhea worldwide and is associated with gut dysbiosis and intestinal damage. Clostridium butyricum MIYAIRI 588 (CBM 588) contributes significantly to reduce epithelial damage. However, the impacts of CBM 588 on antibacterial therapy for CDI are not clear. Here we show that CBM 588 enhanced the antibacterial activity of fidaxomicin against C. difficile and negatively modulated gut succinate levels to prevent C. difficile proliferation and downregulate tumor necrosis factor-α (TNF-α) producing macrophages in the colon lumina propria (cLP), resulting in a significant decrease in colon epithelial damage. Additionally, CBM 588 upregulated T cell-dependent pathogen specific immunoglobulin A (IgA) via interleukin (IL)-17A producing CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.